Jessica Fye
Stock Analyst at JP Morgan
(3.95)
# 493
Out of 4,827 analysts
182
Total ratings
53.06%
Success rate
9.98%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $512 → $515 | $429.60 | +19.88% | 8 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $10 → $13 | $9.92 | +31.05% | 6 | May 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $245 | $159.39 | +53.71% | 11 | May 2, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $355 → $350 | $308.00 | +13.64% | 16 | May 1, 2025 | |
| INCY Incyte | Maintains: Neutral | $70 → $68 | $59.73 | +13.85% | 6 | Apr 21, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $55 → $58 | $67.73 | -14.37% | 12 | Apr 21, 2025 | |
| ONC BeiGene | Maintains: Overweight | $311 → $317 | $235.94 | +34.36% | 1 | Apr 21, 2025 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $54 → $50 | $29.71 | +68.29% | 5 | Apr 14, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $28 | $17.44 | +60.55% | 4 | Apr 10, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $47 → $45 | $32.82 | +37.11% | 4 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $280 → $328 | $258.35 | +26.96% | 5 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $40 → $33 | $24.38 | +35.36% | 12 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $98.41 | +112.38% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $92 | $65.63 | +40.18% | 7 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.46 | +65.98% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $124 → $122 | $94.78 | +28.72% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $59.82 | +82.21% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $30.38 | -14.42% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.71 | +156.19% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $32.70 | +65.14% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $45.24 | -13.79% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $9.05 | +43.65% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.62 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $6.36 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $0.89 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $10.82 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $32.05 | +137.13% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.68 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.27 | +1,632.28% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.69 | +915.82% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.39 | -8.13% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.34 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.66 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.32 | - | 1 | Feb 8, 2018 |
Vertex Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $512 → $515
Current: $429.60
Upside: +19.88%
BioCryst Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.92
Upside: +31.05%
Ascendis Pharma
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $159.39
Upside: +53.71%
United Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $355 → $350
Current: $308.00
Upside: +13.64%
Incyte
Apr 21, 2025
Maintains: Neutral
Price Target: $70 → $68
Current: $59.73
Upside: +13.85%
Halozyme Therapeutics
Apr 21, 2025
Maintains: Neutral
Price Target: $55 → $58
Current: $67.73
Upside: -14.37%
BeiGene
Apr 21, 2025
Maintains: Overweight
Price Target: $311 → $317
Current: $235.94
Upside: +34.36%
Immunocore Holdings
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $29.71
Upside: +68.29%
NovoCure
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $17.44
Upside: +60.55%
Ionis Pharmaceuticals
Mar 24, 2025
Maintains: Neutral
Price Target: $47 → $45
Current: $32.82
Upside: +37.11%
Mar 24, 2025
Upgrades: Overweight
Price Target: $280 → $328
Current: $258.35
Upside: +26.96%
Mar 21, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $24.38
Upside: +35.36%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $98.41
Upside: +112.38%
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $65.63
Upside: +40.18%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.46
Upside: +65.98%
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $94.78
Upside: +28.72%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $59.82
Upside: +82.21%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $30.38
Upside: -14.42%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $11.71
Upside: +156.19%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $32.70
Upside: +65.14%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $45.24
Upside: -13.79%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $9.05
Upside: +43.65%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.62
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $6.36
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $0.89
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $10.82
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $32.05
Upside: +137.13%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.68
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.27
Upside: +1,632.28%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.69
Upside: +915.82%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.39
Upside: -8.13%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.34
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.66
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $5.32
Upside: -